Clinical Trial Update: Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity, safety, and lot-to-lot consistency of the Novartis Meningococcal B recombinant vaccine when co-administered with routin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Meningitis

Drugs mentioned

• Novartis Meningococcal B Recombinant Vaccine (recombinant meningococcal B vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Serogroup B Meningococcal Meningitis | Phase 3 | Status: COMPLETED | Results posted: 2015-04-10